AstraZeneca Unveils Ambitious $2.5 Billion Investment in Beijing Amid Ongoing Probe

In a surprising move that underscores its commitment to expanding operations in Asia, AstraZeneca has announced a substantial investment of $2.5 billion in Beijing, despite facing ongoing scrutiny from regulatory bodies. This significant financial commitment is being interpreted as a bold declaration of confidence in the Chinese market and reflects the pharmaceutical giant's long-term strategic ambitions.

Continue reading